[{"address1": "545 Concord Avenue", "address2": "Suite 210", "city": "Cambridge", "state": "MA", "zip": "02138", "country": "United States", "phone": "857 702 9600", "website": "https://www.metaviatx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts. MetaVia Inc. operates as a subsidiary of Dong-A ST Co., Ltd.", "fullTimeEmployees": 9, "companyOfficers": [{"maxAge": 1, "name": "Mr. Heon Kim  Hyung", "age": 48, "title": "CEO, President & Director", "yearBorn": 1977, "fiscalYear": 2025, "totalPay": 516466, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Marshall H. Woodworth", "age": 67, "title": "Chief Financial Officer", "yearBorn": 1958, "fiscalYear": 2025, "totalPay": 405665, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mi-Kyung  Kim", "title": "Chief Scientific Officer", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert  Homolka", "title": "Senior Vice President of Clinical Operations", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. W. Christopher Fang M.D.", "title": "Consulting Chief Medical Officer & Advisor", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael C. Pine", "age": 49, "title": "Senior Vice President of Business Development Advisor", "yearBorn": 1976, "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1767139200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 3.3, "open": 3.34, "dayLow": 2.95, "dayHigh": 3.3975, "regularMarketPreviousClose": 3.3, "regularMarketOpen": 3.34, "regularMarketDayLow": 2.95, "regularMarketDayHigh": 3.3975, "payoutRatio": 0.0, "beta": 0.269, "volume": 538684, "regularMarketVolume": 538684, "averageVolume": 235261, "averageVolume10days": 296380, "averageDailyVolume10Day": 296380, "bid": 3.32, "ask": 8.34, "bidSize": 2, "askSize": 1, "marketCap": 7181273, "fiftyTwoWeekLow": 2.95, "fiftyTwoWeekHigh": 23.54, "allTimeHigh": 1424940.0, "allTimeLow": 2.95, "fiftyDayAverage": 8.27016, "twoHundredDayAverage": 8.851295, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -7357817, "profitMargins": 0.0, "floatShares": 1165964, "sharesOutstanding": 2308294, "sharesShort": 19683, "sharesShortPriorMonth": 18008, "sharesShortPreviousMonthDate": 1764288000, "dateShortInterest": 1767139200, "sharesPercentSharesOut": 0.0085, "heldPercentInsiders": 0.80893, "heldPercentInstitutions": 0.06866, "shortRatio": 0.08, "shortPercentOfFloat": 0.0207, "impliedSharesOutstanding": 2309091, "bookValue": 2.876, "priceToBook": 1.081363, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -16216000, "trailingEps": -10.45, "lastSplitFactor": "1:11", "lastSplitDate": 1764892800, "enterpriseToEbitda": 0.427, "52WeekChange": -0.8557514, "SandP52WeekChange": 0.14725316, "quoteType": "EQUITY", "currentPrice": 3.11, "targetHighPrice": 208.99998, "targetLowPrice": 40.0, "targetMeanPrice": 98.5, "targetMedianPrice": 72.5, "recommendationMean": 1.33333, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 4, "totalCash": 14283000, "totalCashPerShare": 6.488, "ebitda": -17228000, "totalDebt": 79000, "quickRatio": 1.694, "currentRatio": 1.737, "debtToEquity": 1.248, "returnOnAssets": -0.58407, "returnOnEquity": -1.68181, "freeCashflow": -11055375, "operatingCashflow": -16310000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "MTVA", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "corporateActions": [], "postMarketTime": 1768611311, "regularMarketTime": 1768597201, "exchange": "NCM", "messageBoardId": "finmb_630763379", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -5.75758, "regularMarketPrice": 3.11, "shortName": "MetaVia Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1470403800000, "postMarketChangePercent": 0.0, "postMarketPrice": 3.11, "postMarketChange": 0.0, "regularMarketChange": -0.19, "regularMarketDayRange": "2.95 - 3.3975", "epsTrailingTwelveMonths": -10.45, "fiftyDayAverageChange": -5.16016, "fiftyDayAverageChangePercent": -0.6239493, "twoHundredDayAverageChange": -5.741296, "twoHundredDayAverageChangePercent": -0.648639, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "longName": "MetaVia Inc.", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 235261, "fiftyTwoWeekLowChange": 0.15999985, "fiftyTwoWeekLowChangePercent": 0.054237235, "fiftyTwoWeekRange": "2.95 - 23.54", "fiftyTwoWeekHighChange": -20.43, "fiftyTwoWeekHighChangePercent": -0.86788446, "fiftyTwoWeekChangePercent": -85.57514, "dividendDate": 1577750400, "earningsTimestampStart": 1755001800, "earningsTimestampEnd": 1755520200, "isEarningsDateEstimate": true, "displayName": "MetaVia", "trailingPegRatio": null, "__fetch_time": "2026-01-17"}]